Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Ibrutinib
Related studies linked through entity extraction aliases.
Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.
- Status
- TERMINATED
- Phase
- PHASE2
Phase II Trial GA101 Inbrutinib B CLL
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
- Status
- WITHDRAWN
- Phase
- PHASE2
Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults
- Status
- COMPLETED
- Phase
- PHASE1
Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
- Status
- COMPLETED
- Phase
- PHASE2
Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
- Status
- WITHDRAWN
- Phase
- PHASE1
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
- Status
- COMPLETED
- Phase
- PHASE2
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program
- Status
- COMPLETED
- Phase
- N/A
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1